Drug
TBAJ-876 clinical trials
Also written TBAJ876 and sorfequiline.
- studies test it
- 3
- open now
- 1
- in phase 3
- 0
- first study started
- 2022
Keep track of what changes. Save the TBAJ-876 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
Global Alliance for TB Drug Development (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses TBAJ-876 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TBRecruitingPhase 2Global Alliance for TB Drug DevelopmentNCT07672405Written as sorfequiline
- Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary TuberculosisActive, not recruitingPhase 2Global Alliance for TB Drug DevelopmentNCT06058299Written as sorfequiline
- A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy AdultsCompletedPhase 1Global Alliance for TB Drug DevelopmentNCT05526911Written as TBAJ-876
As the comparator · 1 — what is tested is compared with TBAJ-876
Codes
What other systems call TBAJ-876 · ClinicalTrials.gg INT001454
- MeSH (NLM) C000711567TBAJ-876One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711567 | TBAJ-876 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.